Ionis And AstraZeneca's CARDIO-TTRansform Trial Of Eplontersen In ATTR-CM Misses Primary Endpoint

Ionis Pharmaceuticals and AstraZeneca reported Phase 3 CARDIO-TTRansform results for eplontersen in adults with ATTR-cardiomyopathy, but the trial did not meet its primary endpoint (a composite cardiovascular measure). The miss is a clear clinical setback versus expectations and likely raises uncertainty around future development and timelines for the program.

Analysis

Ionis Pharmaceuticals and AstraZeneca reported Phase 3 CARDIO-TTRansform results for eplontersen in adults with ATTR-cardiomyopathy, but the trial did not meet its primary endpoint (a composite cardiovascular measure). The miss is a clear clinical setback versus expectations and likely raises uncertainty around future development and timelines for the program.